Core Insights - Senseonics Holdings, Inc. (SENS) presented its first real-world evidence for the Eversense 365 continuous glucose monitoring (CGM) system, demonstrating strong performance over a full year of use [1][4] Company Performance - The Eversense 365 system has shown strong patient adherence with an average transmitter wear time of 93.8% and a Time in Range (TIR) of 66%, indicating effective glycemic control [6][7][8] - The integration of Eversense 365 with automated insulin delivery systems has shown promising early results, with a TIR of 77% in initial users [10] - Senseonics reported a significant increase in total revenues for the third quarter of 2025, rising to $8.1 million from $4.3 million year-over-year, primarily driven by U.S. adoption [12] - The company achieved a gross profit of $3.5 million in the latest quarter, a notable improvement from a gross loss of $4.1 million in the previous year [13] Market Position and Trends - The global blood glucose monitoring devices market is projected to grow from $15.53 billion in 2025 to $30.18 billion by 2033, with a compound annual growth rate (CAGR) of 8.8% from 2026 to 2033, driven by the rising prevalence of diabetes and an aging population [11] - Following the announcement of the real-world evidence, SENS shares increased by 11.8% in a single trading session, although the stock has seen a decline of 27.9% over the past six months [3]

Core Insights - The Eversense 365 Continuous Glucose Monitoring (CGM) system has demonstrated sustained performance and positive real-world impact over a full year, showcasing strong patient adherence and effective glycemic outcomes [1][2][3] Group 1: Product Performance - Eversense 365 achieved an average transmitter wear time of 93.8%, with consistent results across the first and second six-month periods, indicating reliable use of the system [4] - The mean Glucose Management Indicator (GMI) was reported at 7.14%, and the mean Time in Range (TIR) was 66%, reflecting effective glycemic control [4] - Over 75% of users met hypoglycemic targets, highlighting the system's accuracy in low glucose ranges, which is critical for patient safety [5] Group 2: Age Group Analysis - The analysis indicated that Eversense 365 provided positive outcomes across all age groups, with the >65 year-old population achieving a mean GMI of 6.99% and a mean TIR of over 70% [5] - Young adults (aged 18-25) also showed promising results, with a mean GMI of 7.3% and over 90% average wear time, indicating strong adherence [6] Group 3: Market Expansion and Future Prospects - Senseonics plans to launch Eversense 365 in select European markets following its CE mark approval in January 2026, building on its commercial momentum in the US [9] - The company is also analyzing early data from the twiist™ Automated Insulin Delivery (AID) system, which is compatible with Eversense 365, showing encouraging glucose outcomes [7][8]

Core Insights - The company transitioned from a partnered model with Ascensia to a fully integrated developer, manufacturer, and direct seller to gain agility and eliminate revenue sharing [1] Financial Performance - Achieved 60% year-over-year revenue growth in 2025, driven by a 103% increase in new patient starts following the U.S. launch of Eversense 365 [1] - Improved gross margins to over 50% by year-end 2025, aided by the shift toward a consignment sales model and higher-margin 365-day sensor sales [1] Market Expansion - Expanded the domestic prescriber base by over 80% year-over-year, reflecting increased clinical confidence in the long-term implantable CGM system [1] Product Integration - Successfully integrated with Sequel's twiist automated insulin delivery system, marking the company's first entry into the Type 1 pump-integrated market [1] Operational Improvements - Internalized the EON Care Group inserter network to address clinical bottlenecks, with approximately 25% of U.S. insertions now performed by this in-house team [1]

Financial Data and Key Metrics Changes - In 2025, the company achieved full-year revenue of over $35 million, growing approximately 60% year-over-year from less than $23 million in 2024 [5][27] - Gross margins improved to greater than 50% by the end of 2025, up from around 25% the previous year [5][27] - The net loss for 2025 was $69.1 million, a decrease from a net loss of $78.6 million in 2024 [27][28] Business Line Data and Key Metrics Changes - U.S. revenue for Q4 2025 was $12.1 million, while revenue outside the U.S. was $2.2 million [24] - The number of Eversense users in the U.S. more than doubled from 2024 to 2025, with new patient starts growing 103% [5][20] - The number of providers actively prescribing Eversense grew more than 80% year-over-year [21] Market Data and Key Metrics Changes - The company expects Europe to contribute about 20% of total revenue in 2026 following the launch of Eversense 365 [41] - The company anticipates full-year 2026 global net revenue to be approximately $58 million-$62 million, representing year-over-year growth of 65%-76% [28][29] Company Strategy and Development Direction - The company transitioned all commercial activities from Ascensia Diabetes Care back to Senseonics, enhancing operational efficiency and control [7][8] - The integration with Sequr Med Tech's twiist Automated Insulin Delivery System is a significant milestone, expected to simplify life for patients requiring insulin [10] - The company plans to launch Eversense 365 in several European markets in Q2 2026, with a dedicated sales force [12][106] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory for 2026, driven by strategic decisions made in 2025 and the integration of commercial operations [6][32] - The company noted that Q4 is typically the strongest quarter due to insurance deductibles being met, and expects similar trends in 2026 [11][29] - Management highlighted the importance of patient retention and the effectiveness of direct-to-consumer marketing strategies [17][18] Other Important Information - The company raised capital from institutional investors and executed a reverse stock split, beginning trading on Nasdaq [10] - Research and development expenses decreased in 2025 due to the completion of clinical trials for Eversense 365 [25][28] Q&A Session Summary Question: Trends in new patient starts at the beginning of the year - Management noted that new patient growth continues as expected, with January typically being the softest month due to patient resets [37] Question: Contribution of Europe and twiist to revenue guidance - Management indicated that Europe is expected to contribute about 20% of revenue in 2026, with unique economics for each company involved in the twiist integration [39][41] Question: Seamlessness of the commercial transition from Ascensia - Management confirmed that the transition was straightforward in the U.S., with nearly 100% of employees transitioning smoothly [44] Question: Growth of the prescriber base and patient starts - Management expressed optimism about the potential for accelerated growth in the prescriber base and new patient starts, supported by increased awareness and DTC investments [50] Question: Challenges in expanding the EonCare inserter network - Management stated that the expansion is primarily dependent on volume and demand, with no significant barriers to increasing the number of inserters [81] Question: Timeline for the rollout in Europe - Management expects the transition to occur in Q2 2026, with some tenders potentially extending into early fall [105][106]

Financial Data and Key Metrics Changes - In 2025, the company achieved full-year revenue of over $35 million, growing approximately 60% year-over-year from less than $23 million in 2024 [5][24] - Gross margins improved to greater than 50% by the end of 2025, up from around 25% the previous year [5][24] - The net loss for 2025 was $69.1 million, a decrease from a net loss of $78.6 million in 2024 [24] Business Line Data and Key Metrics Changes - U.S. revenue for the fourth quarter of 2025 was $12.1 million, while revenue outside the U.S. was $2.2 million [21] - The number of patients using Eversense in the U.S. doubled, with new patient starts growing by 103% [5][17] - The active prescriber base grew more than 80% year-over-year, reflecting increased awareness and confidence in the Eversense 365 system [17] Market Data and Key Metrics Changes - The company expects Europe to contribute about 20% of total revenue in 2026, driven by the launch of Eversense 365 [40] - The company anticipates full-year 2026 global net revenue to be approximately $58 million-$62 million, representing year-over-year growth of 65%-76% [25] Company Strategy and Development Direction - The company transitioned all commercial activities from Ascensia Diabetes Care back to Senseonics, enhancing control and operational efficiency [7][8] - The integration with Sequel Med Tech's twiist Automated Insulin Delivery System is a significant milestone, expected to simplify life for patients requiring insulin [9] - The company plans to launch Eversense 365 in Germany, Italy, Spain, and Sweden, with a dedicated European sales force [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory for 2026, supported by strategic decisions made in 2025 [6][12] - The company noted that the fourth quarter is typically the strongest due to insurance deductibles being met, and expects similar seasonality in 2026 [10][26] - Management highlighted the importance of patient retention and the effectiveness of direct-to-consumer marketing strategies [14][15] Other Important Information - The company raised capital from institutional investors and executed a reverse stock split, beginning trading on Nasdaq [9] - Cash, restricted cash, and cash equivalents totaled $94.3 million as of December 31, 2025 [25] Q&A Session Questions and Answers Question: Trends in new patient starts early in the year - Management noted that new patient growth continues as expected, with encouraging interest in the Sequel product [35] Question: Contribution of Europe and twiist to revenue guidance - Management expects Europe to be about 20% of revenue in 2026, with the twiist product launch contributing positively [40] Question: Seamlessness of the commercial transition from Ascensia - The transition was described as straightforward, with nearly 100% of employees successfully moving to Senseonics [43][44] Question: Growth of the prescriber base and patient base - Management indicated that they expect to double the patient base again in 2026, with potential for acceleration in prescriber growth [49][52] Question: Challenges in expanding the EonCare inserter network - Management stated that there are no significant barriers to expanding the network, but it is dependent on volume to justify additional inserters [80] Question: Expected timeline for the European rollout - The rollout is expected to occur in the second quarter of 2026, with some tenders potentially extending into early fall [104]

Financial Data and Key Metrics Changes - In 2025, the company achieved full-year revenue of over $35 million, growing approximately 60% year-over-year from less than $23 million in 2024 [5][25] - Gross margins improved to greater than 50% by the end of 2025, up from around 25% previously [5][24] - The net loss for 2025 was $69.1 million, a decrease from $78.6 million in 2024, indicating improved financial performance [25][26] Business Line Data and Key Metrics Changes - U.S. revenue for the fourth quarter of 2025 was $12.1 million, while revenue outside the U.S. was $2.2 million [21] - The number of patients using Eversense in the U.S. doubled, with new patient starts growing by 103% [5][18] - The active prescriber base grew more than 80% year-over-year, reflecting increased awareness and confidence in the Eversense 365 system [18] Market Data and Key Metrics Changes - The company expects Europe to contribute about 20% of total revenue in 2026, driven by the launch of Eversense 365 [40] - The company anticipates full-year 2026 global net revenue to be approximately $58 million-$62 million, representing year-over-year growth of 65%-76% [26] Company Strategy and Development Direction - The company transitioned all commercial activities from Ascensia Diabetes Care back to Senseonics, enhancing control and operational efficiency [6][9] - The integration with Sequel Med Tech's twiist Automated Insulin Delivery System is a significant milestone, expected to simplify life for patients requiring insulin [9][17] - The company plans to launch Eversense 365 in Germany, Italy, Spain, and Sweden, with a dedicated European sales force [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory for 2026, supported by strategic decisions made in 2025 [12][31] - The company noted that January is typically a soft month due to patient resets, but they are seeing encouraging interest in new patient starts associated with the Sequel product [36] - Management highlighted the importance of direct-to-consumer (DTC) marketing and patient retention as key growth drivers moving forward [14][16] Other Important Information - The company raised capital from institutional investors and strategic partners, executed a reverse stock split, and began trading on Nasdaq [9] - Cash, restricted cash, and cash equivalents totaled $94.3 million as of December 31, 2025 [26] Q&A Session Summary Question: Trends in new patient starts at the beginning of the year - Management noted that new patient growth continues as expected, with January typically being the softest month due to resets, but they are seeing encouraging interest with the Sequel product [36] Question: Contribution of Europe and twiist to revenue guidance - Management indicated that they expect Europe to contribute about 20% of revenue in 2026, with the twiist product launch expected to enhance revenue [40] Question: Seamlessness of the transition from Ascensia - Management confirmed that the transition in the U.S. was straightforward, with nearly 100% of employees transitioning smoothly [43] Question: Growth of the prescriber base and patient starts - Management expressed optimism about the potential for accelerated growth in the prescriber base and new patient starts, supported by increased DTC investments [53] Question: Challenges in expanding the EonCare inserter network - Management stated that the primary factor for expanding the EonCare network is volume, and there are no significant barriers to increasing the number of inserters [80] Question: Long-term investment expectations - Management indicated that while commercial spend will continue to grow with revenue, it will not increase at the same magnitude as in 2026, and R&D expenses are expected to stabilize in the following years [83]

Core Insights - Senseonics Holdings, Inc. reported a fourth quarter 2025 revenue of $14.3 million, marking a 72% increase year-over-year, and a full year revenue of $35.3 million, up 57% from 2024 [1][4][10]. Financial Performance - Fourth quarter 2025 gross profit was $7.7 million, an increase from $4.0 million in the same quarter of 2024, attributed to favorable margins on the Eversense 365 product sales and lower fixed manufacturing costs [5][11]. - Research and development expenses decreased to $8.8 million in Q4 2025 from $9.4 million in Q4 2024, primarily due to the completion of clinical trials for Eversense 365 [6][12]. - Selling, general and administrative expenses rose significantly to $19.8 million in Q4 2025 from $8.9 million in Q4 2024, driven by increased marketing and sales commission expenses [7][13]. - The net loss for Q4 2025 was $20.8 million, compared to a net loss of $15.5 million in Q4 2024, reflecting higher expenses related to commercialization efforts [9][14]. Strategic Developments - The company received CE Mark approval for the Eversense 365 in the European Union, allowing for commercialization in Europe [1][7]. - Senseonics launched the twiist Automated Insulin Delivery (AID) System integrated with the Eversense 365 CGM system in the U.S. [7]. - The company plans to expand Eversense 365 compatibility with AID systems and complete the Gemini pivotal trial in 2026, which is a key milestone for its innovation pipeline [3][15]. Market Position and Growth - Senseonics achieved a 103% growth in new patients in the U.S. in 2025 compared to 2024, largely due to effective direct-to-consumer marketing [7]. - The number of active prescribers increased by over 80% from 2024 to 2025, indicating strong growth in the healthcare provider channel [7]. Future Outlook - For 2026, Senseonics expects global net revenue to be approximately $58-$62 million, representing a year-over-year growth of 65% to 76% as the company transitions commercialization from Ascensia and enhances its sales and marketing infrastructure [15].

Company Overview - Senseonics has launched the full U.S. availability of its Eversense 365 Continuous Glucose Monitoring (CGM) system, integrated with Sequel Med Tech's twiist Automated Insulin Delivery (AID) system for type 1 diabetes patients [1][7] - The Eversense 365 CGM system offers a wear time of up to 365 days, significantly longer than the maximum of 15 days for other approved CGM devices from competitors like DexCom and Abbott [2][7] Financial Performance - Senseonics reported total revenues of $21 million, which is considerably lower than competitors DexCom and Abbott, who recorded $5.6 billion and $3.4 billion in sales related to CGM devices, respectively, in the first nine months of 2025 [4] - The company expects total revenues for 2026 to be in the range of $58-$62 million, representing an increase of 65% to 76% over 2025 revenue [12] Market Dynamics - The total CGM devices market size was valued at $13.66 billion in 2024 and is projected to grow at a CAGR of 15.4%, reaching $49.87 billion by 2033, driven by the rising prevalence of diabetes and technological advancements [10] - The integration of Eversense 365 with the twiist AID system is expected to enhance customer adoption and drive sales growth in 2026 [4][8] Recent Developments - Senseonics received CE Mark approval for the Eversense 365 CGM system and plans to launch it in Germany, Italy, Spain, and Sweden in the coming months [11] - The company reported a 71% year-over-year increase in total revenues for the fourth quarter of 2025, with new patients in the U.S. increasing by 103% from the previous year [12]

Core Insights - Senseonics Holdings, Inc. (SENS) has achieved a significant commercialization milestone with the launch of the Eversense 365 continuous glucose monitor (CGM) integrated with the twiist automated insulin delivery (AID) system, marking the first pairing of a one-year, implantable CGM with an AID platform [2][3][7] Company Developments - The integration with Sequel MedTech enhances diabetes management by reducing sensor changes and enabling automated insulin adjustments, with broader availability expected by March 2026 [3][10] - The Eversense 365's implantable design allows for uninterrupted glucose monitoring for up to one year, addressing common issues associated with frequent sensor changes [9] - SENS reported a strong improvement in its third-quarter 2025 financial performance, with total revenue rising to $8.1 million from $4.3 million year-over-year, driven by a 160% increase in new patient growth in the U.S. [12] - The company achieved a gross profit of $3.5 million in the quarter, a significant improvement from a gross loss of $4.1 million a year ago, indicating progress in cost structure and operating efficiency [14] Market Position and Trends - Following the announcement of the Eversense 365 launch, SENS shares gained 8%, although they have declined 28.8% over the past six months compared to a 10.5% decline in the industry [4] - The global blood glucose monitoring devices market is projected to grow from $15.53 billion in 2025 to $30.18 billion by 2033, expanding at a CAGR of 8.8% from 2026 to 2033, driven by the increasing prevalence of diabetes [11]

Financial Data and Key Metrics Changes - In Q3 2025, net revenue grew by 90% to $8.1 million compared to $4.3 million in the prior year period, driven by Eversense 365 US revenue of $6.4 million and $1.7 million from outside the US [15][18] - Gross profit was $3.5 million, an increase of $7.5 million from the prior year, primarily due to improved margins on the 365-day product sales [17] - Net loss decreased to $19.5 million, or $0.43 loss per share, compared to a net loss of $24 million, or $0.77 loss per share in Q3 2024 [18] Business Line Data and Key Metrics Changes - The third quarter saw a 160% increase in new patient shipments year-over-year, contributing to the overall revenue growth [5] - New insertions increased nearly 150% year-over-year and more than 50% sequentially, reflecting accelerating adoption of Eversense 365 [6] - Approximately 60% of new patients in Q3 originated from direct-to-consumer (DTC) advertising, with 40% from healthcare provider (HCP) referrals [6] Market Data and Key Metrics Changes - The number of providers actively prescribing Eversense grew by more than 55% year-over-year, indicating broadening awareness and confidence in the 365-day system [7] - Eon Care accounted for approximately one quarter of all insertions nationwide, enhancing access and standardizing patient experience [8] Company Strategy and Development Direction - The company executed a memorandum of understanding with Ascensia Diabetes Care to reassume control of Eversense commercialization, allowing for better control over strategy and investments [4] - The CE Mark application for Eversense 365 in Europe was submitted in February, with expectations for approval before the end of 2025 [8] - The company anticipates gross margins to grow to roughly 50% in 2026 and reach approximately 70% at scale for the unified business [13][21] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth trajectory, highlighting record new patient starts and the effectiveness of DTC marketing [24] - The company expects full-year 2025 global net revenue to be approximately $35 million, with a significant portion anticipated in Q4 due to new patient starts and reorders [19][20] - Management noted that cash utilization in 2025 is expected to be approximately $60 million, with a cash balance of $111.3 million as of September 30 [22] Other Important Information - The company is focused on expanding access to its unique system and advancing technology to simplify glucose testing for people with diabetes [13] - The transition from Ascensia is expected to enhance operational efficiency and improve margins [10][21] Q&A Session Summary Question: Can you discuss the growth opportunities in DTC? - Management noted a significant increase in switchers from existing CGM systems, with 90% of new patients coming from this group, primarily from Dexcom and Libre [28][29] Question: What is the expected timeline for the integration with Twist? - The first patients are expected to start in early Q1 2026, with a ramp-up anticipated later in the year [31][32] Question: How is the inserter network evolving? - The Eon network is crucial for expanding access, with a focus on training providers and increasing the number of inserters [36] Question: What is the status of private payers transitioning to bundled payment reimbursement? - Management expects continued transitions, with significant progress made in the first half of the year [40] Question: Can you provide an update on the CE Mark for Eversense 365? - The CE Mark application is in the final stages of review, with expectations for approval soon [72]